ŗ£½ĒĘĘ½ā°ę

  • Compare Products
Menu
Account
Access free e-books featuring techniques, tips, and protocols to move your research forward.   Explore Now >

CellPoreā„¢ Delivery Cartridges

Single-use mechanoporation cartridges for the CellPoreā„¢ Transfection System, enabling efficient intracellular delivery into immune cells, HSPCs, and hPSCs

Loading...
 

CellPoreā„¢ Delivery Cartridges

Single-use mechanoporation cartridges for the CellPoreā„¢ Transfection System, enabling efficient intracellular delivery into immune cells, HSPCs, and hPSCs

From: 303 CAD
Catalog #
(Select a product)
Single-use mechanoporation cartridges for the CellPoreā„¢ Transfection System, enabling efficient intracellular delivery into immune cells, HSPCs, and hPSCs

Product Advantages

  • Achieve direct cytosolic delivery with controlled, transient mechanoporation using the CellPoreā„¢ Transfection System
  • Maintain delivery efficiency and viability with single-use cartridges for a range of immune, stem, and engineered cell types
  • Streamline your setup and post-mechanoporation handling with pre-assembled cartridges that includes an insert for handling the cell & cargo mixture, as well as its collection tube
  • Use in combination with CellPoreā„¢ Delivery Media to support reproducible results from optimization through routine runs
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.
  1. CellPore™ Transfection System
    CellPoreā„¢ Transfection System

    Cell mechanoporation system for transfection & intracellular delivery

  2. CellPore™ Delivery Media
    CellPoreā„¢ Delivery Media

    Delivery media specially designed to achieve optimal transfection efficiency and high viability of immune cells, HSPCs, and hPSCs when used with the CellPoreā„¢ Transfection System

  3. CellPore™ FITC-Dextran
    CellPoreā„¢ FITC-Dextran

    Fluorescent tracer for visualizing and optimizing intracellular delivery efficiency with CellPoreā„¢ Transfection System

Overview

Use CellPoreā„¢ Delivery Cartridges with the CellPoreā„¢ Transfection System to enable cytosolic delivery of diverse cargo, including nucleic acids (e.g. siRNA, mRNA, self-amplifying RNA), ribonucleoproteins (e.g. Cas9 RNPs), proteins, and other biomolecules to a variety of cell types. These cartridges feature integrated microchannels (constrictions) of specific dimensions that leverage mechanical deformation to achieve transient non-toxic disruption (mechanoporation) of the cell membrane. This physical delivery method offers a gentler approach, making it an ideal solution for sensitive and hard-to-transfect cells while preserving cell viability and function. Each cartridge comes pre-assembled, and includes an insert for handling the cell & cargo mixture, as well as its collection tube for easy and streamlined post-mechanoporation handling. Together, each CellPoreā„¢ Delivery Cartridge supports sample volumes ranging from 20 to 200 Ī¼L.

CellPoreā„¢ Delivery Cartridges are currently available in two constriction sizes, each specifically designed to accommodate a broad range of cell types.

CellPoreā„¢ Delivery Cartridges 300 are compatible with:
ā€¢Human unactivated pan T cells
ā€¢Human unactivated CD4 T cells
ā€¢Human unactivated CD8 T cells
ā€¢Human unactivated Regulatory T cells,
ā€¢Human unactivated Natural Killer (NK) cells
ā€¢Human unactivated B cells
ā€¢Human monocytes
ā€¢Human peripheral blood mononuclear cells (PBMCs)
ā€¢Human CD34+ hematopoietic stem and progenitor cells (HSPCs)
ā€¢Mouse T cells

CellPoreā„¢ Delivery Cartridges 500 are compatible with:
ā€¢Human induced pluripotent stem cells (iPSCs)
ā€¢Human Embryonic stem cells (ESCs)

CellPoreā„¢ Delivery Cartridges are recommended for use with CellPoreā„¢ Delivery Media and the CellPoreā„¢ Transfection System to support optimal transfection efficiency and viability during mechanoporation.

For more information about CellPoreā„¢, including the intracellular delivery technology used in the CellPoreā„¢ Transfection System, visit the CellPoreā„¢ overview page.
Application
Genome Editing
Brand
CellPore
Area of Interest
Disease Modeling, Drug Discovery and Toxicity Testing, Immunology

Data Figures

Optimizing CellPoreā„¢ Delivery Pressure for Efficient Transfection of hPSCs Using FITC-Dextran

Figure 1. Optimizing CellPoreā„¢ Delivery Pressure for Efficient Transfection of hPSCs Using FITC-Dextran

Newly passaged hPSC lines were cultured in complete mTeSRTM Medium for 7 days or until reaching 70% confluency. FITC-dextran was delivered to 3.5 x 105 cells per reaction in increasing pressure (5 - 25 psi). Immediately after delivery, cells were analyzed by flow cytometry to determine cargo delivery efficiency and cell viability. Conditions that maximized delivery efficiency with limited impacts to hPSC viability were determined to be 15 psi across 3 lines tested: (A) SCTi003-A hiPSC, (B) WLS-1C hiPSC, and (C) H9 hESC lines. The ā€Endocytosisā€ condition indicates a control where cells are incubated in the presence of FITC-dextran without mechanoporation. ā€œUntreatedā€ indicates an unmanipulated sample without FITC-dextran. Data are presented as mean Ā± SD (n = 3).

The CellPoreā„¢ Transfection System Enables Reliable Cas9-RNP Editing Across a Wide Range of Cell Numbers

Figure 2. The CellPoreā„¢ Transfection System Enables Reliable Cas9-RNP Editing Across a Wide Range of Cell Numbers

RNP complexes targeting the B2M gene (1:2.5 Cas9:sgRNA mol ratio) were delivered to a range of hPSC numbers per reaction (from 3.5 Ɨ 105 up to 2 Ɨ 106) in 50 ĀµL reactions at 15 psi. Cells were cultured for 2 days post-transfection to allow sufficient time for MHC-I surface marker knockout. Comparable viability, editing efficiency, and expansion were obtained across the cell number range tested for (A) SCTi003-A hiPSCs, (B) WLS-1C hiPSCs, and (C) H9 hESCs. No cargo indicates mechanoporation of hPSCs without RNP complexes at 3.5 Ɨ 105 cells per reaction. Data are presented as mean Ā± SD (n = 3).

Gene-Edited hPSCs Manipulated by CellPoreā„¢ and Maintained in mTeSRā„¢ Plus Are of High Cell Quality

Figure 3. Gene-Edited hPSCs Manipulated by CellPoreā„¢ and Maintained in mTeSRā„¢ Plus Are of High Cell Quality

(A) Gene-edited hESC (H9) and hiPSC (WLS-1C, SCTi003-A) maintained in mTeSRā„¢ Plus on CorningĀ® MatrigelĀ® Matrix continue to exhibit classic hPSC morphology throughout the culture with densely packed, multilayered colonies. (B) hPSCs manipulated by CellPoreā„¢ (orange bars) harvested at Day 14 post-transfection were characterized for markers of the undifferentiated state, with > 90% of cells manipulated by CellPoreā„¢ (orange bars) staining positive for TRA-1-60 (left) and OCT4 (right), as determined by flow cytometry. Graphs show average expression (Ā± standard deviation) results from analyses of 3 independent experiments. Genetic characterization using single nucleotide polymorphism array (SNPa) profiling confirmed no genetic perturbation across all 3 lines (data not shown).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-2175
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0998
Lot #
All
Language
English

Resources and Publications

Educational Materials (10)

Brochure
Brochure
Gene Editing Human Peripheral Blood Natural Killer Cells Using the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Peripheral Blood Natural Killer Cells Using the CellPoreā„¢ Transfection System
Gene Editing Human CD34+ Hematopoietic Stem and Progenitor Cells with the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human CD34+ Hematopoietic Stem and Progenitor Cells with the CellPoreā„¢ Transfection S...
Gene Editing Human Unactivated T Cells with the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Unactivated T Cells with the CellPoreā„¢ Transfection System
Gene Editing Human Pluripotent Stem Cells (hPSCs) Using the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Pluripotent Stem Cells (hPSCs) Using the CellPoreā„¢ Transfection System
CellPoreā„¢: For Gentle Intracellular Delivery
1:54
Video
CellPoreā„¢: For Gentle Intracellular Delivery
How to Use the CellPoreā„¢ Transfection System
8:00
Video
How to Use the CellPoreā„¢ Transfection System
Transform Intracellular Delivery Using the CellPoreā„¢ Transfection System
32:51
Webinar
Transform Intracellular Delivery Using the CellPoreā„¢ Transfection System
Scientific Poster
Legal Statement:

The purchase of a CellPoreā„¢ Transfection System, CellPoreā„¢ Delivery Cartridges, and associated reagents (ā€œCellPoreā„¢ Productsā€) conveys to the purchaser a limited, non-exclusive, non-transferable license to use CellPoreā„¢ Products, in accordance with ŗ£½ĒĘĘ½ā°ę's Terms and Conditions of Sale and all applicable laws and regulations, and solely for research-use-only applications (which applications exclude any commercial application or any therapeutic, prophylactic, diagnostic application, as well as any development and/or commercialization of products therewith or developed therefrom). CellPoreā„¢, SQZā„¢, Cell Squeezeā„¢, and Empower Cells to Change Livesā„¢ are trademarks of ŗ£½ĒĘĘ½ā°ę Technologies Canada Inc., following its acquisition of SQZ Biotech. Nothing in this agreement grants the purchaser any rights to use these trademarks without prior written permission from ŗ£½ĒĘĘ½ā°ę. ŗ£½ĒĘĘ½ā°ę or its licensor(s) grant no additional license rights other than those explicitly granted herein, and except for such limited license rights, all other intellectual property and proprietary rights in and to CellPoreā„¢ Products are and shall remain the exclusive property of ŗ£½ĒĘĘ½ā°ę and its licensors. The purchaser of CellPoreā„¢ Products agrees to prevent unauthorized use, access, copying, or disclosure of any intellectual property comprised in CellPoreā„¢ Products. The purchaser shall not, and shall not permit anyone to, copy, create any derivative work, reverse engineer, disassemble, decompile, or make improvements to CellPoreā„¢ products. Users and purchasers of CellPoreā„¢ products hereby grant to ŗ£½ĒĘĘ½ā°ę exclusive ownership and all rights, title, and interest in and to any improvements made, by purchasers or users, to the CellPoreā„¢ products (including any improvements by purchasers or users to the intellectual property directly related to CellPoreā„¢ products), provided however that the user or purchaser who makes the improvement retains a limited, non-transferable license to use such improvement for its internal, non-commercial research use, in accordance with this agreement, only so long as such user or purchaser is in compliance with this agreement. All data, information, and results (to the extent they do not constitute improvements of CellPoreā„¢ products) entered, stored, compiled, generated, and/or analyzed by purchasers of CellPoreā„¢ products using the CellPoreā„¢ products in accordance with all of the foregoing shall be the property of such purchaser. CellPoreā„¢ Transfection System and CellPoreā„¢ Delivery Cartridges (ā€œCellPoreā„¢ Productsā€) are protected by patents in the U.S. and elsewhere. More information can be found at www.cellpore.com. The list of products and patents contained therein are subject to change as a result of routine prosecution and dependent on the patent life cycle as determined by the laws of each jurisdiction in which a relevant patent is in effect.



Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ŗ£½ĒĘĘ½ā°ę, REFER TO WWW.ŗ£½ĒĘĘ½ā°ę.COM/COMPLIANCE.

Copyright Ā© 2026 ŗ£½ĒĘĘ½ā°ę. All rights reserved.